A seismic shift in pediatric medical care has arrived with the FDA’s approval of Ryoncil (remestemcel-L-rknd), a ...

Doctors and specialists at the Murdoch Children's Research Institute in Melbourne, Australia, are studying and reprogramming ...

This is a significant departure from traditional cancer treatments that rely on killing cancer cells, often leading to severe ...

A Philadelphia cell therapy developer has initiated its first human testing of a potential cancer treatment. Vittoria ...

Bicistronic CAR T-cell therapy can produce durable complete responses in pediatric patients with relapsed or refractory B-ALL, data suggest.

The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...

More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.

While gene therapy has emerged as a promising alternative for treating beta-thalassemia, hematopoietic stem cell ...

You know that moment when life takes an unexpected turn? That’s exactly what happened when I started researching stem cell ...

Black Group Investment Holding Pte Ltd (Black Group) and Zenzic Oasis Holding Pte Ltd (Zenzic Oasis) today announced that ...

Chimeric antigen receptor T-cell or CAR T therapy shows promise for patients with refractory or relapsing B-cell lymphomas.

Chad Stevens traveled from Idaho to Omaha's Nebraska Medical Center, where he became the hospital's first patient to receive ...